Please use this identifier to cite or link to this item: http://hdl.handle.net/11054/1852
Full metadata record
DC FieldValueLanguage
dc.contributorLindsay, J.en_US
dc.contributorOthman, J.en_US
dc.contributorYong, M.en_US
dc.contributorRitchie, D.en_US
dc.contributorChee, L.en_US
dc.contributorTay, K.en_US
dc.contributorTio, S.en_US
dc.contributorKerridge, I.en_US
dc.contributorFay, K.en_US
dc.contributorStevenson, W.en_US
dc.contributorArthur, C.en_US
dc.contributorChen, S.en_US
dc.contributorKong, David C. M.en_US
dc.contributorGreenwood, M.en_US
dc.contributorPergam, S.en_US
dc.contributorLiu, C.en_US
dc.contributorSlavin, M.en_US
dc.date.accessioned2022-01-27T04:16:01Z-
dc.date.available2022-01-27T04:16:01Z-
dc.date.issued2021-
dc.identifier.govdoc01857en_US
dc.identifier.urihttp://hdl.handle.net/11054/1852-
dc.description.abstractBackground The use of antithymocyte globulin (ATG) in allogeneic hematopoietic cell transplant (HCT) is associated with an increased risk of Epstein–Barr virus (EBV) reactivation and post-transplant lymphoproliferative disorders (PTLD). The dynamics and outcomes of EBV-DNAemia are not well described in this population. Methods We retrospectively assessed the kinetics of EBV-DNAemia after ATG conditioning of HCT recipients. Receiver operating characteristic (ROC) curves were used to assess EBV-DNAemia to predict EBV-PTLD in this group. Results A total of 174/405 (43%) consecutive HCT recipients from two centers met inclusion criteria of ATG conditioned, non-B-cell lymphoma patients. Of these with EBV-DNA measured using standardized IU/ml, 78.6% (92/117) developed EBV-DNAemia: 62% spontaneously resolved; 19% cleared after preemptive rituximab, and 13% developed EBV-PTLD. ROC curve analysis using maximum pre-EBV-PTLD EBV-DNAemia, demonstrated an AUC of 0.912 with EBV-DNAemia of 9782 IU/ml, associated with 82.6% sensitivity and 94.4% specificity for development of EBV-PTLD. Median time for EBV-DNAemia to increase from initial detection to >1000 IU/ml was 7 days; to >10 000 IU/ml, 12 days; and to >100 000 IU/ml, 18 days. Median EBV-DNAemia level prior to administration of rituximab was significantly lower in patients with successful preemptive treatment, compared with those who developed EBV-PTLD (3.41 log10 IU/ml [3.30–3.67] vs. 4.34 log10 IU/ml [3.85–5.13], p = .002; i.e., 2628 IU/ml vs. 21 965 IU/ml, respectively). Conclusions EBV-DNAemia >10 000 IU/ml was the strongest predictor of the development of EBV-PTLD, and progression to this level was rapid in ATG-conditioned HCT recipients. This information may guide EBV-PTLD management strategies in these high-risk patients.en_US
dc.description.provenanceSubmitted by Gemma Siemensma (gemmas@bhs.org.au) on 2022-01-13T23:20:14Z No. of bitstreams: 0en
dc.description.provenanceApproved for entry into archive by Gemma Siemensma (gemmas@bhs.org.au) on 2022-01-27T04:16:01Z (GMT) No. of bitstreams: 0en
dc.description.provenanceMade available in DSpace on 2022-01-27T04:16:01Z (GMT). No. of bitstreams: 0 Previous issue date: 2021en
dc.titleDynamics of Epstein–Barr virus on post-transplant lymphoproliferative disorders after antithymocyte globulin-conditioned allogeneic hematopoietic cell transplant.en_US
dc.typeJournal Articleen_US
dc.type.specifiedArticleen_US
dc.bibliographicCitation.titleTransplant Infectious Diseaseen_US
dc.bibliographicCitation.volume23en_US
dc.bibliographicCitation.issue5en_US
dc.bibliographicCitation.stpagee13719en_US
dc.subject.healththesaurusALLOGENEIC HEMATOPOIETIC CELL TRANSPLANT (HCT)en_US
dc.subject.healththesaurusANTITHYMOCYTE GLOBULIN (ATG)en_US
dc.subject.healththesaurusEPSTEIN-BARR VIRUS (EBV)en_US
dc.subject.healththesaurusPOST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDERS (PTLD)en_US
dc.identifier.doihttps://doi.org/10.1111/tid.13719en_US
Appears in Collections:Research Output

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.